(0.13%) 5 187.70 points
(0.08%) 38 884 points
(-0.10%) 16 333 points
(-0.19%) $78.23
(0.27%) $2.21
(-0.07%) $2 322.60
(-0.23%) $27.48
(0.22%) $990.60
(0.04%) $0.930
(0.14%) $10.91
(0.06%) $0.800
(-0.01%) $91.43
Quarter results tomorrow
(amc 2024-05-09)
Expected move: +/- 6.97%
@ $31.40
Issued: 11 Mar 2024 @ 10:33
Return: -20.38%
Previous signal: Mar 8 - 13:41
Previous signal:
Return: -7.29 %
Live Chart Being Loaded With Signals
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is in phase 2b and one phase 3 clinical trial to treat hypertriglyceridemia; ARO-ANG3 that is in Phase 2b clinical trial to reduce production of angiopoietin-like protein 3; ARO-HSD, which is in Phase 1/2a clinical trial to treat liver diseases; ARO-ENaC, which is in a Phase 1/2a clinical trial to reduce production of the epithelial sodium channel alpha subunit in the airways of the lung; ARO-C3 for the treatment of complement-mediated disease that is in Phase 1/2a clinical trial; ARO-Lung2 for the treatment of chronic obstructive pulmonary disorder; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-XDH to treat uncontrolled gout; ARO-COV for the treatment of COVID-19 and other pulmonary-borne pathogens; and ARO-HIF2, which is in phase 1b clinical trial to treat clear cell renal cell carcinoma...
Stats | |
---|---|
Today's Volume | 647 887 |
Average Volume | 1.23M |
Market Cap | 3.10B |
EPS | $-1.030 ( 2024-02-06 ) |
Next earnings date | ( $-0.0600 ) 2024-05-09 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -8.77 |
ATR14 | $0.0200 (0.08%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-05-02 | Vakiener Victoria | Sell | 1 799 | Common Stock |
2024-04-01 | Hamilton James C | Sell | 6 000 | Common Stock |
2024-03-20 | Lu Hongbo | Buy | 1 000 | Common Stock |
2024-03-19 | Lu Hongbo | Buy | 1 000 | Common Stock |
2024-03-18 | Lu Hongbo | Buy | 1 000 | Common Stock |
INSIDER POWER |
---|
13.81 |
Last 100 transactions |
Buy: 903 379 | Sell: 696 131 |
Volume Correlation
Arrowhead Pharmaceuticals Correlation
10 Most Positive Correlations | |
---|---|
PRDS | 0.893 |
RDUS | 0.892 |
EYPT | 0.874 |
JAKK | 0.869 |
SSYS | 0.868 |
RLAY | 0.864 |
PLRX | 0.864 |
MDXH | 0.863 |
ATLC | 0.86 |
MCRB | 0.859 |
10 Most Negative Correlations | |
---|---|
GMII | -0.885 |
RMRM | -0.871 |
MTSI | -0.87 |
COMT | -0.869 |
MEUSW | -0.861 |
DHC | -0.86 |
ALGM | -0.86 |
SBBP | -0.85 |
VTRU | -0.849 |
BGCP | -0.849 |
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Arrowhead Pharmaceuticals Correlation - Currency/Commodity
Arrowhead Pharmaceuticals Financials
Annual | 2023 |
Revenue: | $240.74M |
Gross Profit: | $228.24M (94.81 %) |
EPS: | $-1.920 |
FY | 2023 |
Revenue: | $240.74M |
Gross Profit: | $228.24M (94.81 %) |
EPS: | $-1.920 |
FY | 2022 |
Revenue: | $243.23M |
Gross Profit: | $232.81M (95.72 %) |
EPS: | $-1.670 |
FY | 2021 |
Revenue: | $138.29M |
Gross Profit: | $0.00 (0.00 %) |
EPS: | $-1.360 |
Financial Reports:
No articles found.
Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is in phase 2b and one phase 3 clinical trial to treat hypertriglyceridemia; ARO-ANG3 that is in Phase 2b clinical trial to reduce production of angiopoietin-like protein 3; ARO-HSD, which is in Phase 1/2a clinical trial to treat liver diseases; ARO-ENaC, which is in a Phase 1/2a clinical trial to reduce production of the epithelial sodium channel alpha subunit in the airways of the lung; ARO-C3 for the treatment of complement-mediated disease that is in Phase 1/2a clinical trial; ARO-Lung2 for the treatment of chronic obstructive pulmonary disorder; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-XDH to treat uncontrolled gout; ARO-COV for the treatment of COVID-19 and other pulmonary-borne pathogens; and ARO-HIF2, which is in phase 1b clinical trial to treat clear cell renal cell carcinoma. It is also involved in the development of JNJ-3989, a subcutaneously administered RNAi therapeutic candidate to treat chronic hepatitis B virus infection; Olpasiran to reduce the production of apolipoprotein A; and ARO-AMG1 for treating genetically validated cardiovascular targets. Arrowhead Pharmaceuticals, Inc. has a license and research collaboration agreement with Janssen Pharmaceuticals, Inc. to develop ARO-JNJ1, ARO-JNJ2, and ARO-JNJ3 RNAi therapeutics for liver-expressed targets; and license and research collaboration agreement with Takeda Pharmaceuticals U.S.A., Inc. to develop RNAi therapeutic candidate as a treatment for liver disease. Arrowhead Pharmaceuticals, Inc. was incorporated in 1989 and is headquartered in Pasadena, California.
About Live Signals
The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.
The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators